Extended-spectrum b-lac-tamase Klebsiella pneu-moniae meningitis treated with tigecycline
To the Editor: Multidrug-resis-tant bacteria are increasing in prev-alence, causing sporadic outbreaks of difficult-to-treat infections. Klebsiella pneumoniae is a gramnegative pathogen that is known to cause both community and nosoco-mial infections. Infections caused by Klebsiella that express extendedspectrum b-lactamases (ESBLs) pose a serious challenge to clini-cians as they are resistant to a broad range of b-lactams, including thirdgeneration cephalosporins, thus complicating therapy and limiting treatment options. Furthermore, patients infected with these strains may have higher mortality rates and may require a longer hospital stay. Patients are generally sicker and have received more antibiotics than patients who are not infected with ESBL-producing strains. 1, 2 We treated a case of ESBL-posi-tive Klebsiella meningitis induced by gunshot trauma, with difficult to remove shrapnel. The patient im-proved with 2 weeks of tigecycline treatment. Earlier we reported a case of multidrug resistant Acinetobacter nosocomial meningitis treated suc-cessfully with tigecycline. 3 A 32-year-old male patient not known to have any chronic illness-es, admitted on 31 August 2008 with a history of a gunshot injury to his lumbar area with opened and shredded meninges. The large bowel was also injured; he under-went laparotomy and bowel resec-tion with primary anastomosis with successful outcome. Many pieces of shrapnel could not be surgically re-moved and were left in the menin-ges and spinal canal. He presented with fever and leaking infected cere-brospinal fluid (CSF) from an open lumbar wound, and was taking sev-eral different antimicrobial agents (ceftriaxone, metronidazole and ciprofloxacin for a week) without good response. He suffered from bilateral lower limb paraplegia and sensory loss below the umbilical level. Several debridement surger-ies and meningeal repairs were at-tempted, but he continued to suffer from an infected CSF leak. Surface swabs grew ESBL-positive Klebsiella pneumonia and Enterococcus fecalis. Serial CSF sampling from the up-per thoracic spine showed repeated growth of K pneumoniae with a similar antibiogram, i.e., sensitive to imipenem, ertapenem, levofloxacin, and ciprofloxacin (tigecycline sen-sitivity was not available either by disk diffusion or Vitek in the spe-cialty hospital laboratory) ( Table  1 ). Blood cultures taken twice one week apart showed no growth.
The patient was initially started on ceftriaxone, ciprofloxacine, teicho-planin, and pipracillin/tazobactam at different intervals during his admission, and then on imipenem plus teichoplanin, but the latter was discontinued as soon as ESBL-Klebsiella was identified from CSF. The patient had seizures that were not controlled. Six days later imi-penem was discontinued and tige--cycline 100 mg loading dose and 50 mg every 12 hours was prescribed for a total duration of 14 days. A week later, parenteral ciprofloxacin was added for 3 days for systemic sepsis. In the meantime he was re-ceiving tigecycline. Two days later, the CSF culture was sterile. The pa-tient was continued on tigecycline and showed remarkable clinical im-provement. A CSF culture follow up showed progressive improve-ment ( Table 1) . He was discharged home afebrile and in relatively good condition. He was well for 2 weeks and then was readmitted with chest pain and shortness of breath, and diagnosed with pulmonary embo-lism to which he succumbed in 3 days. Tigecycline is relatively a novel glycylcycline molecule that escapes the classic resistance mechanisms that bacteria harbor against tetra-cyclines, i.e. drug efflux pumps and protection of ribosomes. Thus, it has expanded antimicrobial cover-age and potent in vitro antibacte-rial activity against a wide range of clinically important gram-posi-tive and gram-negative aerobic bacteria and anaerobes, including Staphylococcus aureus, Enterococcus species, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, most Enterobacteriaceae, and Bacteroides fragilis, but it has limited or no activity against Pseudomonas aeruginosa and reduced activity against Proteus mirabilis. Its licensed indications so far are skin and soft tissue infections and complicated intra-abdominal infections. Studies are currently ongoing for diabetic foot infection, community-acquired pneumonia and nosocomially ac-quired pneumionia (Wyeth com-munication). Thus far no controlled studies are available on treating CNS infections with tigecycline in humans. [3] [4] [5] [6] This is our second case of multidrug-resistant gram-negative meningitis in which tigecycline was used with a successful outcome. 
